A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
At the NCI's Childhood Cancer Data Initiative Symposium, speakers emphasized measures such as data harmonization and the need for longitudinal data collection.
St. Jude investigators are sharing their WGS cancer data through the St. Jude Cloud, as well as tools and pipelines to help other researchers analyze and use it.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.
A Chinese study involving NIPS data from almost two million pregnant women found that a new bioinformatic approach improves the detection of cancer.
The researchers created a resource of cancer dependencies and developed a framework to prioritize existing cancer drug targets and suggest new ones.
American Society of Clinical Oncology presentations show the unmet need for methods to predict autoimmune toxicities in checkpoint blockade-treated individuals.